Parkinson's drug market status and prospects
April 11 is World Day of Parkinson's disease. With the global aging society, the rapid development of Parkinson's disease (PD) and prescription drugs in recent years much attention. According to IMS statistics, in 2009, the overall market, anti-Parkinson drugs Sell Amount expected to be 40 billion U.S. dollars, global nervous system drugs accounted for 10% of market.
According to the World Parkinson's Disease Association statistics show that more than 500 million worldwide have Parkinson's patients, the disease is the second stroke sequelae, epilepsy, nervous system damage after the first three kinds of diseases. Epidemiological analysis of China: China syndrome The incidence of Parkinson disease accounts for about 1% of the elderly population, people over 65 years of age incidence rate of about 2%. At present, more than 170 Parkinson's patients have been people, and the newly discovered every year nearly 10 million patients with Parkinson disease. Elderly health care in the sense of the whole society under the influence of differentiation, the development of anti-Parkinson's drug market is not very balanced, and there are still a large gap between theoretical data.
New hot pursuit of cross-border medicine
In the April 2006 meeting of the American Academy of Neurology 58th Annual Meeting, adopted a new "guide to diagnosis and treatment of Parkinson's disease", so that clinical therapy of Parkinson's disease tends to sound reasonable. Currently, for new and old anti-Parkinson's disease drugs more than 20 varieties only. Anti-Parkinson's drug products with domestic and international restructuring, as well as national health insurance system, continuous improvement and personal spending for health care costs increase, anti-Parkinson's drug market showing a trend of rapid growth (see Table 1). In the "independent" drug market year after year warming trend, the price of expensive new drugs led to refresh the market share, while the treatment program has been expanded in clinical.
According to IMS statistics: In 2008, the global anti-Parkinson's drug market reached 3.158 billion U.S. dollars, an increase of 7.89%, compared with the previous year's growth rate has been significant change (see Figure 1). Among them, the world's eight largest prescription drug market (U.S., Canada, France, Germany, Britain, Italy, Spain and Japan), 500 drugs, the main varieties of anti-Parkinson drugs Saquinavir, Enka his friends, ropinirole, to be Dopamine class and Leishajilan a large variety of such sales accounted for 5 of this market, 95% (see Figure 2), showing a high degree of concentration. In 2009, sales of anti-Parkinson drugs increases and the situation down, the overall market sales are expected to reach 40 billion U.S. dollars, global nervous system drugs accounted for 10% of the market. With the increasing degree of aging, Parkinson's treatment drugs will become part of the new hot spot for transnational pharmaceutical chase.
Recent years, dopamine agonists in the hot foreign market situation, these drugs are gradually introduced to China and become anti-Parkinson's prescription drug market hot varieties. Degeneration of dopamine neurons can be bypassed by direct activation of dopamine receptors play a role in treatment, but also has anti-depressant, antioxidant effect and protect the nerve function. For early Parkinson's patients, dopamine agonists and levodopa monotherapy have the same effect. Early use of dopamine agonists, levodopa use can be delayed, postponed levodopa complications.
According to "China Parkinson's disease treatment guidelines," second edition, the domestic clinical use of the drug levodopa class, anti-cholinergic, promote dopamine release agents and dopamine agonists, monoamine oxidase B inhibitor 5 kinds of drug. "National Basic Health Insurance , Work injury insurance and maternity insurance Drug List, "2009 edition collection contains 11 of Parkinson's disease therapy, A drug is levodopa, amantadine and trihexyphenidyl. Group B drugs Duo Basi hydrazine, carbidopa, levodopa / carbidopa, selegiline, memantine, Primaquine, Piribedil, entacapone, etc., remove the bromine Pavilion and has been hidden delisting of the pergolide, added memantine, Primaquine, Piribedil, entacapone and other four varieties.
Shanghai Medicine Industrial Research Institute Information Center released the "China Hospitals pattern" data show that in 2008, the domestic sample hospitals in 22 cities neural class pharmaceutical sales reached 3.515 billion yuan, accounting for 5.91% hospitals all use of drugs, growth over the same period the previous year a 32.54% annual compound growth rate has reached 30.4%. Among them, the anti-drugs market Pajinsenya nervous system drugs accounted for about 2.84%, the year the treatment of Parkinson's disease drug sample hospitals had reached 100 million yuan.
I am an expert from Mp3 Player Manufacturers, usually analyzes all kind of industries situation, such as babyliss curl iron , true ceramic pro hair straightener.
Processing your request, Please wait....
